November 29, 2018

Dr. Wataru Akahata, CEO and Founder of VLP Therapeutics was  Selected by the Government of Japan as a 2018 Researcher of Significant Contribution to Science  Japan’s National Institute of Science and Technology Policy (NISTEP) and the Japan Ministry of Education, Culture, Sports, Science and Technology (MEXT) ( An announcement by MEXT in Japanese appears at


Dr. Akahata was selected for this honor for successfully utilizing the Company’s VLP technology to develop multiple vaccines.  Dr. Akahata is among eleven researchers selected for this honor and will be hosted by Masahiko Shibayama, the Minister of Education, Culture, Sports, Science and Technology on January 10, 2019 in Tokyo, Japan.


“I am pleased and honored that I have been selected as a researcher that contributes to science.  We will continue to develop vaccines against cancer and infectious diseases, said Chief Executive Officer, Dr. Wataru Akahata.


About VLP Therapeutics:

VLP Therapeutics was established in 2013 with a mission to create next-generation virus-like particles to transform traditional vaccine therapies. We are focusing on cancer and infectious disease vaccines. VLP Therapeutics modifies viruses to target cells in two ways: 1) delivery of substantial antigen on the surface of the virus; and 2) direct insertion of genetic material inside the virus. Our virus-like particles have proven to be highly immunogenic in multiple animal models and we anticipate initiating a human trial of our Malaria vaccine in early 2019. The company is headquartered in Gaithersburg, Maryland.